These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27207777)

  • 41. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells.
    Duan Z; Brakora KA; Seiden MV
    Mol Cancer Ther; 2004 Jul; 3(7):833-8. PubMed ID: 15252144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
    Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
    J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.
    Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N
    J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
    Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
    Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.
    Gurler H; Yu Y; Choi J; Kajdacsy-Balla AA; Barbolina MV
    Int J Mol Sci; 2015 Feb; 16(2):3419-33. PubMed ID: 25658796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
    Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
    Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
    Li Y; Sun J; Gao S; Hu H; Xie P
    Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer.
    Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
    Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
    Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
    Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer].
    Tang J; Cao L; Yi H; Tang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
    Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
    Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
    Zhu X; Li Y; Xie C; Yin X; Liu Y; Cao Y; Fang Y; Lin X; Xu Y; Xu W; Shen H; Wen J
    Int J Cancer; 2014 Sep; 135(6):1286-96. PubMed ID: 24510775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
    Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
    Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.
    Zhang Z; Peng H; Wang X; Yin X; Ma P; Jing Y; Cai MC; Liu J; Zhang M; Zhang S; Shi K; Gao WQ; Di W; Zhuang G
    Mol Cancer Ther; 2017 Sep; 16(9):1739-1750. PubMed ID: 28572168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficient and tumor-specific knockdown of MTDH gene attenuates paclitaxel resistance of breast cancer cells both in vivo and in vitro.
    Yang L; Tian Y; Leong WS; Song H; Yang W; Wang M; Wang X; Kong J; Shan B; Song Z
    Breast Cancer Res; 2018 Sep; 20(1):113. PubMed ID: 30227879
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.
    Guo Y; Tian P; Yang C; Liang Z; Li M; Sims M; Lu L; Zhang Z; Li H; Pfeffer LM; Yue J
    Pharm Res; 2015 Mar; 32(3):769-78. PubMed ID: 25823356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
    Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
    J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.